Skip to content

Net Income at other companies

Baxter International logo
Baxter InternationalBAX
-$15M-112%
PTH
Pelthos Therapeutics Inc.PTHS
-$10.24M-420%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$166.56M+1.8%
RFL
Rafael Holdings, Inc.RFL
-$4.23M+11.6%
Opko Health logo
Opko HealthOPK
-$54.85M+18.9%
Organon logo
OrganonOGN
$146M+67.8%

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+142%
Enterprise value$90.91M+212%
P/S2.3×+1.4×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's net income?
Cumberland Pharmaceuticals (CPIX) reported net income of -$3.29M in Q1 2026.
How has Cumberland Pharmaceuticals's net income changed year-over-year?
Cumberland Pharmaceuticals's net income decreased by 363.3% year-over-year, from $1.25M to -$3.29M.
What is the long-term trend for Cumberland Pharmaceuticals's net income?
Over 4 years (2021 to 2025), Cumberland Pharmaceuticals's net income has grown at a -5.6% compound annual growth rate (CAGR), from -$3.6M to -$2.86M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.